GPX4 and hepatocellular carcinoma: Pien-Tze-Huang, a Chinese patent medicine approved by China Food and Drug Administration, may effectively improve the microenvironment of LF and inhibit the occurrence of HCC through triggering ferroptosis of tumor cells via suppressing the SLC7A11-GSH-GPX4 axis [228].